Skip to main content
SpringerLink
Log in

The pathophysiological role of fibrinolysis inhibitors

  • III. Proteins Inhibiting Coagulation and Fibrinolysis
  • Published:
Ricerca in clinica e in laboratorio

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Ambrus C. M., Choi T. S., Cunnanan Z.: Prevention of hyaline membrane disease with plasminogen. A cooperative study—J. Amer. med. Ass.237, 1837, 1977.

    Article  CAS  Google Scholar 

  2. Aoki N.: Natural inhibitors of fibrinolysis—Progr. cardiovasc. Dis.21, 267, 1979.

    Article  CAS  Google Scholar 

  3. Aoki N., Moroi M., Sakata Y., Yoshida N., Matsuda M.: Abnormal plasminogen. A hereditary molecular abnormality found in a patient with recurrent thrombosis—J. clin. Invest.61, 1186, 1978.

    Article  PubMed  CAS  Google Scholar 

  4. Astrup T.: Fibrinolysis in the organism—Blood11, 781, 1956.

    PubMed  CAS  Google Scholar 

  5. Astrup T.: Fibrinolysis. An overview. In:Davidson J. F., Rowan R. M., Samama M. M., Desnoyers P. C. (Eds): Progress in chemical fibrinolysis and thrombolysis. Raven Press, New York, 1978; vol. 3, p. 1.

    Google Scholar 

  6. Castel M., Horellou M.-H., Conard J., Samama M.: Immunochemical determination of histidine-rich glycoprotein in healthy subjects and in a clinical population—Haemostasis11, S1, 60, 1982. (Abstract no. 107).

    Google Scholar 

  7. Chmielewska J., Ranby M., Wiman B.: Evidence for a rapid inhibitor to tissue plasminogen activator in plasma—Thrombos. Haemost.50, 193, 1983. (Abstract no. 591).

    Google Scholar 

  8. Clayton J. K., Anderson J. A., McNico, G. P.: Preoperative prediction of postoperative deep vein thrombosis—Brit. med. J.ii, 910, 1976.

    Google Scholar 

  9. Collen D.: Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma—Europ. J. Biochem.69, 209, 1976.

    Article  PubMed  CAS  Google Scholar 

  10. Collen D.: α2-antiplasmin inhibitor deficiency—Lanceti, 1039, 1979.

    Article  Google Scholar 

  11. Collen D.: On the regulation and control of fibrinolysis—Thrombos. Haemost.43, 77, 1980.

    CAS  Google Scholar 

  12. Collen D.: Mechanisms of inhibition of tissue-type plasminogen activator in blood—Thrombos. Haemost.50, 678, 1983.

    CAS  Google Scholar 

  13. Emeis J. J., Van Hinsberch V. W. M., Verheyen J. H., Wijngaards G.: Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells—Biochem. biophys. Res. Commun.110, 392, 1983.

    Article  PubMed  CAS  Google Scholar 

  14. Fearnley G. R.: Fibrinolysis—Advanc. Drug Res.7, 107, 1973.

    CAS  Google Scholar 

  15. Gurewich V., Hyde E., Lipinski B.: The resistance of fibrinogen and soluble fibrin monomer in blood to degradation by a potent plasminogen activator from cadaver limbs—Blood46, 555, 1975.

    PubMed  CAS  Google Scholar 

  16. Hoylaerts M., Rijken D. C., Lijnen H. R., Collen D.: Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin—J. biol. Chem.257, 2912, 1982.

    PubMed  CAS  Google Scholar 

  17. Isaacson S., Nilsson I. M.: Defective fibrinolysis in blood and vein walls in recurrent ‘idiopathic’ venous thrombosis—Acta chir. scand.138, 313, 1972.

    Google Scholar 

  18. Jacobsson H., Hogstorp H., Saldeen T.: Post-traumatic variation of a plasminogen-binding and a non-plasminogen-binding form of histidine-rich glycoprotein in plasma—Thrombos. Haemost.50, 300, 1983. (Abstract no. 950).

    Google Scholar 

  19. Johansson L., Hedner U., Nilsson I. M.: A family with thromboembolic disease associated with deficient fibrinolytic activity in vessel wall—Acta med. scand.203, 477, 1978.

    PubMed  CAS  Google Scholar 

  20. Juhan-Vague I., Rijken D. C., Collen D.: Extrinsic plasminogen activator levels in clinical plasma samples—Haemostasis11, S1, 11, 1982.

    Google Scholar 

  21. Juhan-Vague I., Rijken D. C., Mendez C., Mofrman B., Collen D.: Measurement of tissue-type plasminogen activator (t-PA) inhibitors, and reaction products in plasma. In: 7th Meeting of the International Society of Haematology. European and African Division. Barcelona. 1983. (Abstract no. 96).

    Google Scholar 

  22. Kluft C., Vellenga E., Brommer E. J. P.: Homozygous α2-antiplasmin deficiency—Lanceti 206, 1979.

    Article  Google Scholar 

  23. Koie K., Ogata K., Kamiya T., Takamatsu J., Kohakura M.: α2-plasmin inhibitor deficiency (Miyasato disease)—Lancetii, 1334, 1978.

    Article  Google Scholar 

  24. Korninger C., Stassen J. M., Collen D.: Turnover of human extrinsic (tissue-type) plasminogen activator in rabbits—Thrombos. Haemost.46, 658, 1981.

    CAS  Google Scholar 

  25. Lijnen H. R., Collen D.: Interaction of plasminogen activators and inhibitors with plasminogen and fibrin—Semin. Thrombos Hemost.8, 2, 1982.

    Article  CAS  Google Scholar 

  26. Lijnen H. R., Collen D.: α2-antiplasmin. In:Murano G. (Ed.): Proteinase inhibitors of human plasma. P. J. D. Publ., 1984. (in press).

  27. Lijnen H. R., Hoylaerts M., Collen D.: Isolation and characterization of a human plasma protein with affinity for the lysine binding sites in plasminogen. Role in the regulation of fibrinolysis and identification as histidine-rich glycoprotein—J. biol. Chem.255, 10214, 1980.

    PubMed  CAS  Google Scholar 

  28. Lijnen H. R., Jacobs G., Colen D.: Histidine-rich glycoprotein in a normal and a clinical population—Thrombos. Res.22, 519, 1981.

    Article  CAS  Google Scholar 

  29. Marsh N.: Fibrinolysis. John Wiley and Sons, Chichester, 1981.

    Google Scholar 

  30. Miles L. A., Plow E. F., Donnelly K. J., Hougie C., Griffin J. H.: A bleeding disorder due to deficiency of α2-antiplasmin.—Blood59, 1246, 1982.

    PubMed  CAS  Google Scholar 

  31. Moroi M., Aoki N.: Isolation and characterization of α2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis—J. biol. Chem.251, 5956, 1976.

    PubMed  CAS  Google Scholar 

  32. Müllertz S.: Mechanism of activation and effect of plasmin in blood. Ph.D. Thesis. Eijnar Munksgaard. Copenhagen, 1956.

    Google Scholar 

  33. Müllertz S., Clemmensen I.: The primary inhibitor of plasmin in human plasma—Biochem. J.159, 545, 1976.

    PubMed  Google Scholar 

  34. Nilsson I. M., Hedner U., Isaacson S.: Phenformin and ethyloestrenol in recurrent venous thrombosis—Acta med. scand.198, 107, 1975.

    PubMed  CAS  Google Scholar 

  35. Rakoczi I., Chamone D., Collen D., Verstraete M.: Prediction of postoperative leg vein thrombosis in gynaecological patients—Lanceti, 509, 1978.

    Article  Google Scholar 

  36. Reich E.: Plasminogen activator: secretion by neoplastic cells and macrophages. In:Reich E., Rifkin D. B., Shaw E. (Eds): Proteases and biological control. Cold Spring Harbor Laboratory, 1975; p. 333.

  37. Rijken D. C., Hoylaerts M., Collen D.: Fibrinolytic properties of one chain and two-chain human extrinsic (tissue-type) plasminogen activator—J. biol. Chem.257, 2920, 1982.

    PubMed  CAS  Google Scholar 

  38. Rijken D. C., Juhan-Vague I., Collen D.: Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay—J. Lab. clin. Med.101, 285, 1983.

    PubMed  CAS  Google Scholar 

  39. Rijken D. C., Juhan-Vague I., DeCock F., Collen D.: Measurement of human tissue-type plasminogen activator by a two-site immunoradiometric assay—J. Lab. clin. Med.101, 274, 1983.

    PubMed  CAS  Google Scholar 

  40. Saito H., Goodnough L. T., Boyle J. M., Heimburger N.: Reduced histidine-rich glycoprotein levels in plasma of patients with advanced liver cirrhosis. Possible implications for enhanced fibrinolysis—Amer. J. Med.73, 179, 1982.

    Article  PubMed  CAS  Google Scholar 

  41. Sherry S., Fletcher A. P., Alkjaersig N.: Fibrinolysis and fibrinolytic activity in man— Physiol. Rev.39, 343, 1959.

    PubMed  CAS  Google Scholar 

  42. Soria J., Soria C., Bertrand O., Lefur M. A., Drouet L., Baudouy Y., Dupuy E., Tobelem G., Caen J.: Congenital abnormal plasminogen: plasminogen Paris I. Relationship with thrombosis—Haemostasis11, S1, 1, 1982. (Abstract no. 1).

    Google Scholar 

  43. Strickland S.: Studies on the role of plasminogen activator in ovulation and early embryogenesis. In:Macnusson S., Ottesen M., Foutman B., Danø K., Neurath H. (Eds): Regulatory proteolytic enzymes and their inhibitors. Pergamon Press, Oxford, 1978; p. 181.

    Google Scholar 

  44. van Mourik J. A., Lawrence D. L., Los toe D. J.: Characterization of a novel inhibitor synthesized by bovine aortic endorhelial cells inculture—Thrombos. Haemost.50, 95, 1983. (Abstract no. 281).

    Google Scholar 

  45. Verheyen J. H., Chang G. I. C., Mullaart E.: Inhibition of extrinsic (tissue-type) plasminogen activator by human plasma: evidence for the occurrence of a fast-acting inhibitor— Thrombas. Haemost50, 294, 1983. (Abstract no 930).

    Google Scholar 

  46. Virchow R.: Gesammelte Abhandlunger zur wissenschafthchen Medizin. Meidinger Sohn und Co., Frankfurt, 1856.

    Google Scholar 

  47. Wijngaaros G., Groeneveld E.: Temporarily increased inhibition by plasma of plasminogen activation activity in severely ill patients—Haemostasis12, 571, 1982.

    Google Scholar 

  48. Wiman B., Collen D.: Molecular mechanism of physiological fibrinolysis—Nature (Lond.)272, 549, 1978.

    Article  CAS  Google Scholar 

  49. Wiman B., Collen D.: On the kinetics of the reaction between human antiplasmin and plasmin—Europ. J. Biochem.84, 573, 1978.

    Article  PubMed  CAS  Google Scholar 

  50. Wohl R. C., Summaria L., Robbins K. C.: Physiological activation of the human plasminogen variants Chicago I and Chicago II—J. biol. Chem.234, 9063, 1979.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Center for Thrombosis and Vascular Research, Department of Medical Research, University of Leuven, K.U.L. Campus Gasthuisberg Herestraat 49, B-3000, Leuven, Belgium

    Henri R. Lijnen & Désire Collen

Authors
  1. Henri R. Lijnen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Désire Collen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lijnen, H.R., Collen, D. The pathophysiological role of fibrinolysis inhibitors. La Ricerca Clin. Lab. 14, 499–505 (1984). https://doi.org/10.1007/BF02904877

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02904877

Keywords

Search

Navigation